 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
ARTICLES |
1 at time of writing, Pharmacotherapy Fellow, College of Pharmacy, Ohio State University, Columbus, OH; now, Assistant Professor, Cooperative Pharmacy Program, University of Texas-Pan American, Edinburg, TX
2 PharmD, Professor of Pharmacy and Division Chair, College of Pharmacy; Professor of Pediatrics and Internal Medicine, College of Medicine and Public Health, Ohio State University and Children's Hospital, Columbus, OH
* To whom correspondence should be addressed. E-mail: nahata.1{at}osu.edu.
 |
Abstract |
|---|
OBJECTIVE: To review the safety and efficacy of selective serotonin-reuptake inhibitors (SSRIs) for the treatment of depression in adults with HIV.
DATA SOURCES: We searched Pre-MEDLINE and MEDLINE (1966-May 2004) using terms including generic names of antidepressants and antiretrovirals, depression, HIV, and acquired immunodeficiency syndrome. All English-language articles were included in this review.
DATA SYNTHESIS: SSRIs may be effective and better tolerated than tricyclic antidepressants in HIV-positive adults. SSRIs did not appear to affect CD4+ cell counts.
CONCLUSIONS: Controlled trials comparing SSRIs are lacking; thus, it is difficult to determine whether one SSRI is more efficacious than another. It appears that most SSRIs may be used in HIV-positive adults. If drug-drug interactions are a concern, sertraline, citalopram, and possibly escitalopram may be considered.
Key Words: adults, antiretrovirals, selective serotonin-reuptake inhibitors,
Reprints: Dr. Nahata, College of Pharmacy, Ohio State University, 500 W. 12th Ave., Columbus, OH 43210-1291, fax 614/292-1335d, nahata.1@osu.edu
 |
 |
 |
 |
 |
 |
 |
